Examkin

Question

Difficulty: HardImmunologic and Inflammatory Processes

A 66-year-old woman is evaluated in the emergency department for a 4-day history of severe, non-bloody diarrhea. She reports having up to 10 watery bowel movements daily, accompanied by diffuse abdominal cramping and a low-grade fever. She has a history of metastatic melanoma and began therapy with pembrolizumab 6 weeks ago. Her temperature is 37.8°C (100.0°F), blood pressure is 110/70 mm Hg, and pulse is 108/min. Physical examination reveals a diffusely tender abdomen with hyperactive bowel sounds, but no rebound tenderness or guarding. Laboratory studies show a serum potassium of 3.1 mEq/L and an elevated C-reactive protein. Stool PCR for *Clostridioides difficile* and routine enteric stool cultures are negative. A flexible sigmoidoscopy reveals diffuse mucosal erythema, loss of vascular pattern, and patchy ulcerations. Biopsy demonstrates a dense lymphoplasmacytic infiltrate expanding the lamina propria. In addition to intravenous fluid resuscitation, which of the following is the most appropriate targeted intervention and its corresponding immunopathologic rationale?

  1. Intravenous methylprednisolone; to suppress unrestricted T-cell activation resulting from the blockade of negative costimulatory signalsAnswer
  2. B
    Oral vancomycin; to empirically treat a resistant *Clostridioides difficile* infection that evaded detection on initial high-sensitivity testing
  3. C
    Loperamide; to provide symptomatic relief of colonic hypermotility while awaiting pharmacokinetic clearance of the monoclonal antibody
  4. D
    Intravenous piperacillin-tazobactam; to prevent bacterial translocation secondary to direct cytotoxic disruption of the rapidly dividing intestinal epithelium
  5. E
    Supportive care and delayed follow-up colonoscopy; to allow for spontaneous resolution of immune complex deposition in the intestinal microvasculature

Answer

Intravenous methylprednisolone; to suppress unrestricted T-cell activation resulting from the blockade of negative costimulatory signals.
Pembrolizumab is an IgG4 monoclonal antibody that targets Programmed Cell Death Protein 1 (PD-1). Normally, the interaction between PD-1 on T cells and PD-L1/PD-L2 on target cells provides a critical negative costimulatory signal that maintains peripheral tolerance and prevents autoimmunity. By blocking this interaction, pembrolizumab enhances the anti-tumor immune response but simultaneously removes the "brakes" on the immune system, leading to unrestrained T-cell activation. This uninhibited cell-mediated immunity can attack healthy host tissues, resulting in immune-related adverse events (irAEs). This patient has severe (Grade 3) immune-related colitis. The standard of care for severe irAEs requires immediately holding the immunotherapy and initiating high-dose systemic corticosteroids, such as intravenous methylprednisolone, to aggressively suppress the hyperactive T-cell response and prevent colonic perforation.

Step-by-Step Solution

1
Identify the clinical syndrome based on the patient's history and presentation.
The patient presents with severe (Grade 3) colitis (10 daily stools, cramping) shortly after initiating pembrolizumab, an immune checkpoint inhibitor.
Recognizing the temporal association between immunotherapy and inflammatory symptoms is critical for establishing a differential diagnosis.
2
Eliminate alternative infectious or cytotoxic etiologies.
Negative highly-sensitive stool PCR effectively rules out C. difficile. The drug class (immunotherapy) rules out direct cytotoxic enteropathy.
Ruling out infection is mandatory before initiating high-dose immunosuppression in any patient with severe colitis.
3
Determine the specific immunopathogenesis of the drug.
Pembrolizumab blocks PD-1, preventing the delivery of negative costimulatory signals to T cells, leading to a break in peripheral tolerance and unregulated tissue damage.
Understanding the mechanism of action explains the biopsy findings (lymphoplasmacytic infiltrate) and guides targeted reversal.
4
Select the appropriate pharmacologic management based on severity.
Grade 3 immune-related adverse events (irAEs) require immediate suspension of the offending agent and administration of high-dose systemic corticosteroids (e.g., IV methylprednisolone).
Prompt immunosuppression halts the cell-mediated destruction of the colon, preventing severe complications like toxic megacolon or perforation.

Key Concept

Immune checkpoint inhibitor-mediated colitis pathogenesis and step-wise management.
Rate this question

Topics

Immunologic and Inflammatory Processes

More questions from this topic